Boehringer Ingelheim GmbH’s new cancer pill Hernexeos, which helped buoy the German drugmaker’s first-half revenue, won’t go on sale in Europe until at least 2028, three years later than in the US.
Sonja Wind is a Healthcare/Consumer Reporter at various esteemed outlets. She covers a diverse range of topics including finance, trading, aviation, and healthcare, with a particular focus on commercial airlines, pharmaceutical manufacturing, and international trade. Sonja's work has been featured in Yahoo Finance Canada, Fortune, Moneyweb, The Irish Times, Yahoo Finance, The Detroit News, ThinkAdvisor, Citywire, BNN Bloomberg, Bloomberg News, The Australian Financial Review, and the Arkansas Democrat-Gazette.















